Akebia Therapeutics, Inc.
AKBANasdaqCIK 1517022HealthcareFiscal year ends Dec 31
Reports and events: 251 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-10-2316:06 ET | 8-K | 3.01 Delisting notice | 0001517022-26-000075 |
| 2026-10-1411:57 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001517022-26-000071 |
| 2026-08-0520:10 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001517022-26-000051 |
| 2026-08-0520:09 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001517022-26-000050 |
| 2026-06-3012:05 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001517022-26-000047 |
| 2026-06-2220:16 ET | 8-K | 5.07 Shareholder vote results | 0001517022-26-000043 |
| 2026-05-0711:24 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001517022-26-000039 |
| 2026-05-0711:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001517022-26-000038 |
| 2026-04-2820:12 ET | DEF 14A | Proxy statementPeriod 2026-04-28 | 0001517022-26-000034 |
| 2026-04-0120:48 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001517022-26-000024 |
| 2026-02-2612:35 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001517022-26-000020 |
| 2026-02-2612:04 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001517022-26-000019 |
| 2026-01-3013:34 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001517022-26-000008 |
| 2026-01-1213:04 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001517022-26-000003 |
| 2025-12-0112:08 ET | 8-K | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001517022-25-000051 |
| 2025-11-1712:54 ET | 8-K | 1.01 Entry into a material agreement | 0001517022-25-000048 |
| 2025-11-1012:36 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001517022-25-000046 |
| 2025-11-1012:04 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001517022-25-000045 |
| 2025-10-2820:37 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001517022-25-000040 |
| 2025-08-0711:38 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0001628280-25-038600 |
| 2025-08-0711:06 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001517022-25-000034 |
| 2025-06-1311:21 ET | 8-K | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results | 0001517022-25-000030 |
| 2025-05-0811:29 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0001628280-25-023460 |
| 2025-05-0811:04 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001517022-25-000027 |
| 2025-04-2920:03 ET | DEF 14A | Proxy statementPeriod 2025-04-29 | 0001517022-25-000023 |
| 2025-03-2020:48 ET | 8-K | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-059327 |
| 2025-03-1311:27 ET | 10-K | Annual reportPeriod 2024-12-31 | 0001628280-25-012470 |
| 2025-03-1311:08 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001517022-25-000017 |
| 2025-02-0713:16 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity | 0001517022-25-000010 |
| 2025-01-1313:05 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001517022-25-000004 |
| 2024-11-0712:16 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0001628280-24-045979 |
| 2024-11-0712:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001517022-24-000075 |
| 2024-10-2212:05 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001517022-24-000070 |
| 2024-10-1611:36 ET | 8-K | 1.01 Entry into a material agreement | 0001517022-24-000067 |
| 2024-08-0811:52 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0001628280-24-035879 |
| 2024-08-0811:06 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001517022-24-000065 |
| 2024-07-1110:05 ET | 8-K | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement | 0001517022-24-000061 |
| 2024-06-2413:03 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001517022-24-000059 |
| 2024-06-1020:09 ET | 8-K | 5.07 Shareholder vote results | 0001517022-24-000057 |
| 2024-05-0911:05 ET | 10-Q | Quarterly reportPeriod 2024-03-31 | 0001628280-24-021945 |
| 2024-05-0911:03 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001517022-24-000050 |
| 2024-04-2521:17 ET | DEF 14A | Proxy statementPeriod 2024-04-25 | 0001517022-24-000045 |
| 2024-04-2312:32 ET | 8-K | 2.03 New direct financial obligation | 0001517022-24-000035 |
| 2024-04-1611:33 ET | 8-K | 1.01 Entry into a material agreement | 0001517022-24-000033 |
| 2024-03-2800:35 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001517022-24-000031 |
| 2024-03-1520:05 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-24-069123 |
| 2024-03-1421:19 ET | 10-K | Annual reportPeriod 2023-12-31 | 0001628280-24-011270 |
| 2024-03-1420:18 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001517022-24-000029 |
| 2024-02-1313:00 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001517022-24-000019 |
| 2024-01-3013:05 ET | 8-K | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity | 0001517022-24-000014 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:13 ET. Listed shows no prices and gives no investment advice.